The Cost Effectiveness of Donafenib Compared With Sorafenib for the First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma in China

BACKGROUND: Recent clinical trials have demonstrated that donafenib has superior efficacy and safety compared with sorafenib in Chinese patients with unresectable or metastatic hepatocellular carcinoma (HCC). The objective of this study was to assess the cost effectiveness of donafenib compared with...

Descripción completa

Detalles Bibliográficos
Autores principales: Meng, Rui, Cao, Yingdan, Zhou, Ting, Hu, Hongfei, Qiu, Yijin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Public Health
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9008355/
https://www.ncbi.nlm.nih.gov/pubmed/35433574
http://dx.doi.org/10.3389/fpubh.2022.794131

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9008355/
https://www.ncbi.nlm.nih.gov/pubmed/35433574
http://dx.doi.org/10.3389/fpubh.2022.794131

Ejemplares similares